In 2012, Flamel Technologies acquired Eclat Pharmaceuticals with a 100% contingency payment offer. Elcat was lured into a deal with a significant upside to their shareholders. What happened subsequently is a lesson for Dealmakers and Sellers. This is an important story with lessons for those pursuing M&A’s.
Contact Us
"*" indicates required fields